Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | G6PD | P11413 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | APAF1 | O14727 | 1/20 | 0.37 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3193700 | 0.84 | MAPT (0.46) | ALDH1A1MAPTKDM4EKMT2AL3MBTL1 | |
| SCHEMBL962867 | 0.84 | MAPT (0.46) | ALDH1A1MAPTKDM4EKMT2AL3MBTL1 | |
| SCHEMBL38662618 | 0.84 | MAPT (0.46) | ALDH1A1MAPTKDM4EKMT2AL3MBTL1 | |
| SCHEMBL10304845 | 0.84 | MAPT (0.42) | ALDH1A1HPGDMAPTKDM4EKMT2A | |
| SCHEMBL13385327 | 0.83 | KDM4E (0.46) | ALDH1A1HPGDMAPTKDM4EKMT2A | |
| SCHEMBL13377068 | 0.82 | KDM4E (0.49) | ALDH1A1MAPTKDM4EKMT2AL3MBTL1 | |
| SCHEMBL3262956 | 0.81 | MAPT (0.43) | ALDH1A1HPGDMAPTKDM4EKMT2A | |
| SCHEMBL14576378 | 0.80 | CRHR1 (0.40) | ALDH1A1MAPTKDM4EKMT2AL3MBTL1 | |
| SCHEMBL8777562 | 0.79 | ESR1 (0.47) | ALDH1A1MAPTKDM4EKMT2AL3MBTL1 | |
| SCHEMBL20288421 | 0.79 | KDM4E (0.34) | ALDH1A1HPGDMAPTKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | BIOTHERYX, INC. | 2019-10-24 | — | — | US | disclosed |
| WO-2019178510-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2019-09-19 | — | — | WO | disclosed |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | BIOTHERYX, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | Bio TheryX, Inc. | 2018-06-21 | — | — | US | disclosed |
| US-9740095-B2 | Green coloring composition for use in color filter, colored film, color filter, and solid-state imaging device | FUJIFILM CORPORATION (JP) | 2017-08-22 | — | — | US | disclosed |
| US-20090295281-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-12-03 | — | — | US | disclosed |
| US-20090261714-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-22 | — | — | US | disclosed |
| US-20090252990-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-10-08 | — | — | US | disclosed |
| EP-2098532-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-09-09 | — | — | EP | disclosed |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-23 | — | — | US | disclosed |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-16 | — | — | US | disclosed |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-07-09 | — | — | US | disclosed |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2009-06-18 | — | — | US | disclosed |
| EP-2055709-A2 | Novel red electroluminescent compounds and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090261714-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, ODC1, LEF1 | ALDH1A1 19/4885HPGD 3242/4885MAPT 2705/4885 |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | ALDH1A1 4848/4885HPGD 1016/4885MAPT 3927/4885 |
| US-20090252990-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, LEF1, ODC1 | ALDH1A1 23/4885HPGD 3274/4885MAPT 2613/4885 |
| US-20180170948-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | ALDH1A1 2758/4885HPGD 4068/4885MAPT 774/4885 |
| US-20090184631-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | ALDH1A2, ODC1, NDUFS2 | ALDH1A1 5/4885HPGD 3079/4885MAPT 1871/4885 |
| US-20090174316-A1 | Novel red electroluminescent compounds and organi electroluminescent device using the same | ALPI, IK, ALDH1A2 | ALDH1A1 59/4885HPGD 3590/4885MAPT 2054/4885 |
| US-20090153037-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | ALDH1A1 5/4885HPGD 3081/4885MAPT 1708/4885 |
| US-20090295281-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | AOX1, LEF1, ODC1 | ALDH1A1 19/4885HPGD 3000/4885MAPT 2879/4885 |
| US-20090184629-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | IK, TYR, EYA2 | ALDH1A1 718/4885HPGD 4254/4885MAPT 1074/4885 |
| US-20090179555-A1 | Novel red electroluminescent compounds and organic electroluminescent device using the same | NDUFS2, ALDH1A2, ODC1 | ALDH1A1 5/4885HPGD 3081/4885MAPT 1708/4885 |
| US-10889593-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | ALDH1A1 2758/4885HPGD 4068/4885MAPT 774/4885 |
| US-10040804-B2 | Compounds targeting proteins, compositions, methods, and uses thereof | CKS1B, IKZF3, EPAS1 | ALDH1A1 2758/4885HPGD 4068/4885MAPT 774/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ALDH1A1 4834/4885HPGD 723/4885MAPT 4037/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | ALDH1A1 4817/4885HPGD 798/4885MAPT 4113/4885 |
| US-20190322683-A1 | COMPOUNDS TARGETING PROTEINS, COMPOSITIONS, METHODS, AND USES THEREOF | CKS1B, IKZF3, EPAS1 | ALDH1A1 2758/4885HPGD 4068/4885MAPT 774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.